Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells $103,159.04 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 332 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $310.72, for a total value of $103,159.04. Following the completion of the transaction, the senior vice president owned 101 shares of the company’s stock, valued at $31,382.72. The trade was a 76.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $311.59, for a total value of $103,447.88.
• On Wednesday, March 11th, Chan Henry Lee sold 341 shares of BeOne Medicines stock. The shares were sold at an average price of $300.00, for a total value of $102,300.00.

BeOne Medicines Price Performance

Shares of NASDAQ ONC opened at $293.27 on Monday. The stock has a market capitalization of $32.18 billion, a price-to-earnings ratio of 65.61 and a beta of 0.50. The business has a 50-day moving average of $300.41 and a 200-day moving average of $321.78. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $227.05 and a fifty-two week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The company had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. As a group, sell-side analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ONC has been the subject of a number of research analyst reports. Wolfe Research initiated coverage on BeOne Medicines in a report on Friday, March 27th. They set an “outperform” rating and a $340.00 price target for the company. Barclays lifted their price target on BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Royal Bank Of Canada lifted their price target on BeOne Medicines from $423.00 to $425.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Wells Fargo & Company initiated coverage on BeOne Medicines in a report on Monday, May 4th. They set an “overweight” rating and a $400.00 price target for the company. Finally, Leerink Partners lifted their price target on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, BeOne Medicines currently has a consensus rating of “Moderate Buy” and a consensus target price of $389.15.

Institutional Investors Weigh In On BeOne Medicines

Several hedge funds have recently bought and sold shares of the stock. Mariner LLC lifted its position in BeOne Medicines by 3.8% during the fourth quarter. Mariner LLC now owns 883 shares of the company’s stock worth $269,000 after acquiring an additional 32 shares during the last quarter. Signaturefd LLC lifted its position in BeOne Medicines by 10.7% during the fourth quarter. Signaturefd LLC now owns 340 shares of the company’s stock worth $103,000 after acquiring an additional 33 shares during the last quarter. Farther Finance Advisors LLC lifted its position in BeOne Medicines by 21.8% during the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after acquiring an additional 39 shares during the last quarter. CWM LLC lifted its position in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares during the last quarter. Finally, Sequoia Financial Advisors LLC lifted its position in BeOne Medicines by 4.1% during the third quarter. Sequoia Financial Advisors LLC now owns 1,281 shares of the company’s stock worth $436,000 after acquiring an additional 50 shares during the last quarter. 48.55% of the stock is currently owned by institutional investors and hedge funds.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.